Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics
Wang, J.; Seo, J. W.; Kare, A. J.; Schneider, M.; Tumbale, S. K.; Wu, B.; Raie, M. N.; Pandrala, M.; Iagaru, A.; Brunsing, R. L.; Charville, G. W.; Park, W. G.; Ferrara, K. W.
Show abstract
We apply spatial transcriptomics and proteomics to select pancreatic cancer surface receptor targets for molecular imaging and theranostics using an approach that can be applied to many cancers. Selected cancer surfaceome epithelial markers were spatially correlated and provided specific cancer localization, whereas the spatial correlation between cancer markers and immune- cell or fibroblast markers was low. While molecular imaging of cancer-associated fibroblasts and integrins has been proposed for pancreatic cancer, our data point to the tight junction protein claudin-4 as a theranostic target. Claudin-4 expression increased [~]16 fold in cancer as compared with normal pancreas, and the tight junction localization conferred low background for imaging in normal tissue. We developed a peptide-based molecular imaging agent targeted to claudin-4 with accumulation to [~]25% injected activity per cc (IA/cc) in metastases and [~]18% IA/cc in tumors. Our work motivates a new approach for data-driven selection of molecular targets.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single-Cell RNA Sequencing Reveals the Effects of Chemotherapy on Human Pancreatic Adenocarcinoma and its Tumor Microenvironment 96%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 96%
- Mapping and modeling human colorectal carcinoma interactions with the tumor microenvironment 96%
Similar papers in this journal
- Deciphering sources of PET signals in the tumor microenvironment of glioblastoma at cellular resolution 94%
- An in vivo screen identifies NAT10 as a master regulator of brain metastasis 94%
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.